Zobrazeno 1 - 10
of 89
pro vyhledávání: '"гепатопротекторы"'
Publikováno v:
Фармакокинетика и Фармакодинамика, Vol 0, Iss 1, Pp 52-57 (2020)
Препараты, содержащие эссенциальные фосфолипиды, в настоящее время широко используются для лечения заболеваний печени. Выбор конкретн
Externí odkaz:
https://doaj.org/article/3b188d352fbb4da49feeb7ddf4f5792f
Publikováno v:
Туберкулез и болезни лёгких, Vol 96, Iss 10, Pp 63-69 (2018)
The article presents the review of the Russian and international studies devoted to the use of hepatoprotectors during anti-tuberculosis treatment, including methionine derivatives and agents containing succinic acid.
Externí odkaz:
https://doaj.org/article/062887c281e049fbbf1102c8d5af8ab8
Autor:
A. A. Petrenko, A. P. Levitsky
Publikováno v:
Journal of Education, Health and Sport, Vol 6, Iss 6, Pp 177-184 (2016)
Petrenko А. A., Levitsky A. P. Гастропротекторная эффективность гепатопротекторов у крыс с токсическим гепатитом = Gastroprotective effects of hepatoprotectors in toxic hepati
Externí odkaz:
https://doaj.org/article/aa7c9881814e47f4abd67534c85916fb
Autor:
E. A. Cherkashina
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 67-71 (2015)
Nonalcoholic fatty liver disease is a chronic disease uniting steatosis, nonalcoholic steatohepatitis and cirrhosis. Nonalcoholic fatty liver disease is associated with obesity and is a component of metabolic syndrome, thus increasing cardiometabolic
Externí odkaz:
https://doaj.org/article/4f0102237ada48e5a03fd52f5e51fbdf
Autor:
O. M. Smirnova
Publikováno v:
Медицинский совет, Vol 0, Iss 2, Pp 57-61 (2014)
Представлен литературный обзор по проблеме неалкогольной жировой болезни печени (НАЖБП), включающий данные об эпидемиологии, патогенез
Externí odkaz:
https://doaj.org/article/38b28c52292d4701ba120ee76f0e2858
Autor:
G. N. Mozhokina, N. A. Elistratova, L. P. Mikhailova, O. V. Makarova, V. S. Sultanov, V. B. Trusov
Publikováno v:
Туберкулез и болезни лёгких, Vol 0, Iss 7, Pp 47-53 (2014)
A model of isoniazid-induced liver damage in fast (females) and slow (males) acetylators was used to study the preventive hepatoprotective effect of the novel drug roprene in doses of 10, 15, and 30 mg/kg as an oil solution. It was found that in term
Externí odkaz:
https://doaj.org/article/197820fa1a4a47a78c6587459d441cc4
Autor:
Editorial Article
Publikováno v:
Медицинский совет, Vol 0, Iss 3, Pp 58-61 (2013)
Для последнего десятилетия характерно повышение пристального внимания к проблеме метаболического синдрома (МС) и тесно связанной с ним
Externí odkaz:
https://doaj.org/article/696c0726494e441d96bc48affd119775
Autor:
E. B. Grishchenko
Publikováno v:
Медицинский совет, Vol 0, Iss 3, Pp 52-57 (2013)
Liver diseases of different types are a common cause of morbidity and mortality. The total number of liver lesions is unknown; however it is estimated to be huge, according to epidemiological studies conducted in different parts of the world.
Externí odkaz:
https://doaj.org/article/cde6b3dfd3ff4061b92d51c384bad8aa
Autor:
L. Y. Ilchenko, T. I. Korovich
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 32-37 (2013)
The article tells about drugs that most often cause undesirable hepatotoxic effects, mechanisms of drug-induced lesions and morphological changes in the liver; the principles of diagnosis and treatment of drug-induced liver disease; characteristics o
Externí odkaz:
https://doaj.org/article/bebc48b8ae0c4e73905d180bd00bfaf5
Autor:
I. G. Pakhomova, Y. P. Uspenskiy
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 89-93 (2013)
The article considers the problem of non-alcoholic fatty liver disease, analyzes the main etiopathogenic aspects and risk factors such as obesity, insulin resistance and other. The treatment regimen with pathogenically relevant drugs, including the n
Externí odkaz:
https://doaj.org/article/d91b454ac46f4f4ba22defd6bd3041d3